Cochrane Summariesbeta

Independent high-quality evidence for health care decision making

There is no evidence that dietary or supplemental omega 3 polyunsaturated fatty acid (PUFA) reduces the risk of cognitive impairment or dementia in healthy elderly persons without pre-existing dementia

Lim W-S, Gammack JK, Van Niekerk JK, Dangour A
Published Online: 
January 21, 2009

Evidence from biological and epidemiological studies suggests that lower omega 3 PUFA intake is associated with an increased risk of dementia. In experimental animal models, dietary enhancement of docosahexanoic acid (a long-chain omega 3 PUFA) slows the expression of Alzheimer's pathology and improves cognitive performance. These findings raise the possibility of similar preventative benefits in humans. Omega 3 PUFA have also being shown to reduce vascular risk, inflammation and oxidative damage. Available clinical studies comparing the occurrence of Alzheimer's disease between elderly persons with different levels of dietary omega 3 PUFA intake, suggest that risk of Alzheimer's disease is significantly reduced among those with higher levels of fish and omega 3 PUFA consumption. However, because these studies are not randomized trials, they provide insufficient evidence to recommend dietary and supplemental omega 3 PUFA for the explicit purpose of dementia prevention.

This review yielded no clinical trials that could confirm or refute the utility of omega 3 PUFA in preventing cognitive impairment or dementia. This is an important area that is in pressing need of further research.

Find the research